Spear Holdings RSC Ltd Takes $34.66 Million Position in Eli Lilly and Company $LLY

Spear Holdings RSC Ltd purchased a new position in Eli Lilly and Company (NYSE:LLY) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 37,681 shares of the company’s stock, valued at approximately $34,658,000. Eli Lilly and Company comprises about 3.5% of Spear Holdings RSC Ltd’s portfolio, making the stock its 13th largest position.

A number of other hedge funds have also recently modified their holdings of the company. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Osbon Capital Management LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Basso Capital Management L.P. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $30,000. Maseco LLP grew its position in shares of Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after buying an additional 28 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research analyst reports. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Leerink Partners upped their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. UBS Group lifted their target price on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Finally, Royal Bank Of Canada lifted their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,283.64.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,185.31 on Friday. The business has a fifty day moving average price of $1,132.74 and a 200-day moving average price of $1,039.05. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a market capitalization of $1.12 trillion, a PE ratio of 42.11, a PEG ratio of 1.47 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 34.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide met its primary endpoints in two additional Phase 3 trials, with patients losing up to about 20.8% to 22.6% of body weight, strengthening the case for a highly valuable new obesity franchise. Reuters: Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
• Positive Sentiment: Lilly said it now plans to file for FDA approval in the first quarter of 2027, keeping the drug on track for a potential future launch even though the filing was pushed back. CNBC: Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
• Neutral Sentiment: Lilly is also expanding its pipeline through the acquisition of AtaiBeckley, a psychedelic medicine biotech, which could support longer-term diversification but is not an immediate earnings driver. Motley Fool: Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here’s What You Need to Know.
• Negative Sentiment: The FDA filing for retatrutide was delayed from an earlier timeline, and Lilly said it needs more manufacturing and quality-control data, which adds a modest regulatory timing risk. Yahoo Finance: Lilly to file for next-gen obesity drug approval in early 2027
• Negative Sentiment: Novo Nordisk has filed a lawsuit accusing Lilly of misleading weight-loss advertising, creating headline legal risk in the competitive obesity-drug market. Yahoo Finance: How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.